Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q07973

UPID:
CP24A_HUMAN

ALTERNATIVE NAMES:
Cytochrome P450 24A1; Cytochrome P450-CC24

ALTERNATIVE UPACC:
Q07973; Q15807; Q32ML3; Q5I2W7

BACKGROUND:
Cytochrome P450 24A1, essential for vitamin D metabolism and calcium regulation, performs sequential oxidation of calcitriol and calcidiol. This enzyme's activity ensures the proper inactivation and excretion of vitamin D metabolites, maintaining calcium balance within the body.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of 1,25-dihydroxyvitamin D(3) 24-hydroxylase could open doors to potential therapeutic strategies for managing diseases like Hypercalcemia, infantile, 1, highlighting the enzyme's significance in medical research.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.